These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 27712586)

  • 1. Anexelekto (AXL) Increases Resistance to EGFR-TKI and Activation of AKT and ERK1/2 in Non-Small Cell Lung Cancer Cells.
    Tian Y; Zhang Z; Miao L; Yang Z; Yang J; Wang Y; Qian D; Cai H; Wang Y
    Oncol Res; 2016; 24(5):295-303. PubMed ID: 27712586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.
    Rho JK; Choi YJ; Kim SY; Kim TW; Choi EK; Yoon SJ; Park BM; Park E; Bae JH; Choi CM; Lee JC
    Cancer Res; 2014 Jan; 74(1):253-62. PubMed ID: 24165158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer.
    Bae SY; Hong JY; Lee HJ; Park HJ; Lee SK
    Oncotarget; 2015 Apr; 6(12):10146-60. PubMed ID: 25760142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma.
    Wu F; Li J; Jang C; Wang J; Xiong J
    Int J Clin Exp Pathol; 2014; 7(10):6653-61. PubMed ID: 25400744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells.
    Kim D; Bach DH; Fan YH; Luu TT; Hong JY; Park HJ; Lee SK
    Cell Death Dis; 2019 May; 10(5):361. PubMed ID: 31043587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer.
    Wang Y; Xia H; Zhuang Z; Miao L; Chen X; Cai H
    Cell Death Dis; 2014 May; 5(5):e1227. PubMed ID: 24832599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
    Kato Y; Ninomiya K; Ohashi K; Tomida S; Makimoto G; Watanabe H; Kudo K; Matsumoto S; Umemura S; Goto K; Ichihara E; Ninomiya T; Kubo T; Sato A; Hotta K; Tabata M; Toyooka S; Maeda Y; Kiura K
    Cancer Sci; 2018 Oct; 109(10):3149-3158. PubMed ID: 30053332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in
    Okura N; Nishioka N; Yamada T; Taniguchi H; Tanimura K; Katayama Y; Yoshimura A; Watanabe S; Kikuchi T; Shiotsu S; Kitazaki T; Nishiyama A; Iwasaku M; Kaneko Y; Uchino J; Uehara H; Horinaka M; Sakai T; Tanaka K; Kozaki R; Yano S; Takayama K
    Clin Cancer Res; 2020 May; 26(9):2244-2256. PubMed ID: 31953310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
    Zhang Y; Yao K; Shi C; Jiang Y; Liu K; Zhao S; Chen H; Reddy K; Zhang C; Chang X; Ryu J; Bode AM; Dong Z; Dong Z
    Oncotarget; 2015 Dec; 6(42):44274-88. PubMed ID: 26517520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer.
    Han R; Lu CH; Hu C; Dou YY; Kang J; Lin CY; Wu D; Jiang WL; Yin GQ; He Y
    Acta Pharmacol Sin; 2024 Jun; 45(6):1264-1275. PubMed ID: 38438582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The miR‑625‑3p/AXL axis induces non‑T790M acquired resistance to EGFR‑TKI via activation of the TGF‑β/Smad pathway and EMT in EGFR‑mutant non‑small cell lung cancer.
    Du W; Sun L; Liu T; Zhu J; Zeng Y; Zhang Y; Wang X; Liu Z; Huang JA
    Oncol Rep; 2020 Jul; 44(1):185-195. PubMed ID: 32319651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanism research of miR-34a regulates Axl in non-small-cell lung cancer with gefitinib-acquired resistance.
    Xiong R; Sun XX; Wu HR; Xu GW; Wang GX; Sun XH; Xu MQ; Xie MR
    Thorac Cancer; 2020 Jan; 11(1):156-165. PubMed ID: 31777195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Axl is a novel target of celastrol that inhibits cell proliferation and migration, and increases the cytotoxicity of gefitinib in EGFR mutant non‑small cell lung cancer cells.
    Lee YJ; Kim SY; Lee C
    Mol Med Rep; 2019 Apr; 19(4):3230-3236. PubMed ID: 30816529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2.
    Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X
    Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
    Zhang Z; Lee JC; Lin L; Olivas V; Au V; LaFramboise T; Abdel-Rahman M; Wang X; Levine AD; Rho JK; Choi YJ; Choi CM; Kim SW; Jang SJ; Park YS; Kim WS; Lee DH; Lee JS; Miller VA; Arcila M; Ladanyi M; Moonsamy P; Sawyers C; Boggon TJ; Ma PC; Costa C; Taron M; Rosell R; Halmos B; Bivona TG
    Nat Genet; 2012 Jul; 44(8):852-60. PubMed ID: 22751098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer.
    Liu YN; Tsai MF; Wu SG; Chang TH; Tsai TH; Gow CH; Chang YL; Shih JY
    Int J Cancer; 2019 Sep; 145(6):1609-1624. PubMed ID: 31162839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor tissue and plasma levels of AXL and GAS6 before and after tyrosine kinase inhibitor treatment in EGFR-mutated non-small cell lung cancer.
    Nonagase Y; Takeda M; Azuma K; Hayashi H; Haratani K; Tanaka K; Yonesaka K; Ishii H; Hoshino T; Nakagawa K
    Thorac Cancer; 2019 Oct; 10(10):1928-1935. PubMed ID: 31419057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. β-Catenin overexpression is associated with gefitinib resistance in non-small cell lung cancer cells.
    Fang X; Gu P; Zhou C; Liang A; Ren S; Liu F; Zeng Y; Wu Y; Zhao Y; Huang B; Zhang Z; Yi X
    Pulm Pharmacol Ther; 2014 Jun; 28(1):41-48. PubMed ID: 23707949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis.
    Karachaliou N; Chaib I; Cardona AF; Berenguer J; Bracht JWP; Yang J; Cai X; Wang Z; Hu C; Drozdowskyj A; Servat CC; Servat JC; Ito M; Attili I; Aldeguer E; Capitan AG; Rodriguez J; Rojas L; Viteri S; Molina-Vila MA; Ou SI; Okada M; Mok TS; Bivona TG; Ono M; Cui J; Ramón Y Cajal S; Frias A; Cao P; Rosell R
    EBioMedicine; 2018 Mar; 29():112-127. PubMed ID: 29433983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of the HSP27-AKT axis contributes to gefitinib resistance in non-small cell lung cancer cells independent of EGFR mutations.
    Choi SK; Kim M; Lee H; Kwon Y; Cha HJ; Jang SJ; Na Y; Lee YS
    Cell Oncol (Dordr); 2022 Oct; 45(5):913-930. PubMed ID: 35931945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.